Pulmonary Embolism Market
According to the IMARC Group, the pulmonary embolism market reached a value of US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 5.58% during 2024-2034. This can be attributed to the growing use of direct oral anticoagulants (DOACs), which inhibit blood clots while having less drug-drug interactions and do not require constant monitoring.
Pulmonary embolism (PE) refers to a medical condition that develops when a blood clot, usually developing in the legs or deep veins of the body, travels to the lungs as well as blocks one or more of the blood vessels of the lungs. The pulmonary embolism market is expanding rapidly, owing to several key factors. Primarily, the market is driven by the rising incidence of venous thromboembolism (VTE), which is closely linked to sedentary lifestyles, increasing obesity rates, and a growing aging population. Additionally, advancements in diagnostic technologies, such as computed tomography pulmonary angiography (CTPA) and D-dimer tests, are enhancing early detection, thereby fueling the growth of the pulmonary embolism market.
Moreover, the rising adoption of novel anticoagulant therapies, including direct oral anticoagulants (DOACs), is improving treatment outcomes and expanding market opportunities. In addition to these factors, the increasing preference for minimally invasive procedures, such as catheter-directed thrombolysis, is gaining traction due to their reduced recovery times and lower risks of complications. Furthermore, pharmaceutical companies are also investing in research and development to introduce next-generation anticoagulants with better safety profiles and fewer side effects, which is expected to create new growth avenues. Consequently, the integration of artificial intelligence (AI) in diagnostic imaging is revolutionizing disease detection and facilitating timely intervention. The trend toward personalized medicine, which involves tailoring anticoagulant therapy based on individual genetic and physiological factors, is also anticipated to drive the growth of the pulmonary embolism market in the coming years.
Request for a sample of this report: https://www.imarcgroup.com/pulmonary-embolism-market/requestsample
Countries Covered:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Pulmonary Embolism Market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Pulmonary Embolism Market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current Pulmonary Embolism Market drugs and late-stage pipeline drugs.
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
Ask the Analyst for Customization and Explore the Full Report with TOC: http://imarcgroup.com/request?type=report&id=6777&flag=E
Competitive Landscape with key players:
The competitive landscape of the Pulmonary Embolism Market has been studied in the report with the detailed profiles of the key players operating in the market.
- Bristol-Myers Squibb/Pfizer
- Boehringer Ingelheim
- Daiichi Sankyo
- Sanofi aventis
- Bayer/Johnson & Johnson Pharmaceutical
- Supergene
- Translational Sciences
- Anthos Therapeutics
- Daiichi Sankyo
- Tasly Pharmaceutical
Browse other reports by IMARC Group
Hypertriglyceridemia market - https://www.imarcgroup.com/hypertriglyceridemia-market
Hypogonadism market - https://www.imarcgroup.com/male-hypogonadism-market
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
